16790-59-3

Usage

InChI:InChI=1/C12H17NO2/c1-7(14)13-12-4-8-2-9(5-12)11(15)10(3-8)6-12/h8-10H,2-6H2,1H3,(H,13,14)

Upstream product

• 20098-14-0 chemantane 
• 75-05-8 acetonitrile 
• 56674-87-4 4-oxoadamantane-1-carboxylic acid 
• 75-36-5 acetyl chloride 
• 944123-99-3 tert-butyl N-(4-oxoadamantan-1-yl)carbamate 

Relevant academic research and scientific papers

Synthesis and identification of an important metabolite of AKB-48 with a secondary hydroxyl group on the adamantyl ring

Studies on the metabolism of bioactive substances containing the adamantyl moiety have shown that hydroxylation is likely to occur at a tertiary carbon of adamantane. Herein, we report the synthesis and identification of one major metabolite of AKB-48, a new illicit psychoactive substance with a hydroxyl group at a secondary carbon of the adamantyl ring.

Synthetic approaches to physiologically active polycyclic compounds: III. Ritter reaction with ketones of the adamantane and oxahomoadamantane series

Some previously unknown acetamino derivatives were synthesized by the Ritter reaction from ketones of the adamantane and oxahomoadamantane series. The presence of a hydroxy group as substituent in adamantan-2-one gives rise to formation of acetamino derivatives as products of replacement of the hydroxy group and transformation of the carbonyl group.

Ring-fused compound, pharmaceutical composition containing same and application of compound

The invention discloses a ring-fused compound, a preparation method thereof, pharmaceutical composition containing the compound and an application of the compound. A polycyclic compound (I) as well asan isomer, a prodrug, a stable isotopic derivative or pharmacologically acceptable salt of the compound (I) has the following structure. The polycyclic compound has good IDO1 and/or TDO2 inhibition functions, can effectively treat, relieve and/or prevent various diseases which are related with IDO1 and/or TDO2, such as cancer, virus infection, autoimmune diseases or the like.